{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T23:29:43Z","timestamp":1768519783255,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Dutch Organization for Health Research and Development","award":["205200002"],"award-info":[{"award-number":["205200002"]}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ijantimicag.2016.11.027","type":"journal-article","created":{"date-parts":[[2017,2,3]],"date-time":"2017-02-03T00:18:03Z","timestamp":1486081083000},"page":"302-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109"],"prefix":"10.1016","volume":"49","author":[{"given":"Gerjo J.","family":"de Knegt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aart","family":"van der Meijden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corn\u00e9 P.","family":"de Vogel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob E.","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurriaan E.M.","family":"de Steenwinkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0010","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/502S2a","article-title":"Epidemiology: a mortal foe","volume":"502","author":"Paulson","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0015","series-title":"Global tuberculosis report 2015","author":"World Health Organization","year":"2015"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0020","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1093\/jac\/dkv215","article-title":"Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment","volume":"70","author":"Jeong","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0025","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1128\/AAC.01691-15","article-title":"Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis","volume":"60","author":"Tasneen","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0030","doi-asserted-by":"crossref","first-page":"e94462","DOI":"10.1371\/journal.pone.0094462","article-title":"Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis","volume":"9","author":"Wallis","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jac\/dkv316","article-title":"Efflux pump inhibitors: targeting mycobacterial efflux systems to enhance TB therapy","volume":"71","author":"Pule","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0040","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1159\/000109769","article-title":"Importance of the efflux pump systems in the resistance of Mycobacterium tuberculosis to fluoroquinolones and linezolid","volume":"53","author":"Escribano","year":"2007","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.tube.2014.09.002","article-title":"Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy","volume":"94","author":"de Knegt","year":"2014","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0050","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijantimicag.2015.02.025","article-title":"SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model","volume":"46","author":"de Knegt","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0055","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/jac\/dkr500","article-title":"Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine","volume":"67","author":"Abbate","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0060","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1128\/AAC.01462-13","article-title":"Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis","volume":"58","author":"Gupta","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0065","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1164\/rccm.201304-0650OC","article-title":"Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor","volume":"188","author":"Gupta","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0070","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1128\/AAC.04019-14","article-title":"Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model","volume":"59","author":"Gupta","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0075","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/infdis\/jiu095","article-title":"Verapamil, and its metabolite norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to multiple anti-tubercular drugs","volume":"210","author":"Adams","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0080","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1128\/AAC.48.11.4171-4176.2004","article-title":"Inhibition of antibiotic efflux in bacteria by the novel multidrug resistance inhibitors biricodar (VX-710) and timcodar (VX-853)","volume":"48","author":"Mullin","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0085","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1128\/AAC.04271-14","article-title":"The efflux pump inhibitor timcodar improves the potency of antimycobacterial agents","volume":"59","author":"Grossman","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0090","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1128\/AAC.43.6.1317","article-title":"Peptide antibiotics","volume":"43","author":"Hancock","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0095","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1093\/jac\/dkv194","article-title":"Colistin as a potentiator of anti-TB drug activity against Mycobacterium tuberculosis","volume":"70","author":"Bax","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0100","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jpba.2004.11.036","article-title":"Simultaneous estimation of pharmacokinetic properties in mice of three anti-tubercular ethambutol analogs obtained from combinatorial lead optimization","volume":"37","author":"Jia","year":"2005","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0105","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2217\/fmb.12.56","article-title":"Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action","volume":"7","author":"Sacksteder","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tube.2015.08.004","article-title":"Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters","volume":"96","author":"Te Brake","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0115","doi-asserted-by":"crossref","first-page":"660","DOI":"10.3201\/eid1804.110912","article-title":"Drug susceptibility of Mycobacterium tuberculosis Beijing genotype and association with MDR TB","volume":"18","author":"de Steenwinkel","year":"2012","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0120","doi-asserted-by":"crossref","first-page":"4937","DOI":"10.1128\/AAC.00124-12","article-title":"Consequences of noncompliance for therapy efficacy and emergence of resistance in murine tuberculosis caused by the Beijing genotype of Mycobacterium tuberculosis","volume":"56","author":"de Steenwinkel","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0125","article-title":"Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0130","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1093\/jac\/dkq374","article-title":"Time\u2013kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis","volume":"65","author":"de Steenwinkel","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0135","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1128\/JCM.01121-14","article-title":"When does 2 plus 2 equal 5? A review of antimicrobial synergy testing","volume":"52","author":"Doern","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0140","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1183\/09031936.00124614","article-title":"TBNET. Availability, price and affordability of anti-tuberculosis drugs in Europe: a TBNET survey","volume":"45","author":"G\u00fcnther","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0145","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1056\/NEJMoa1407426","article-title":"Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis","volume":"371","author":"Gillespie","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0150","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1016\/S0140-6736(14)62002-X","volume":"385","author":"Dawson","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0155","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1084\/jem.88.1.99","article-title":"The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms","volume":"88","author":"Eagle","year":"1948","journal-title":"J Exp Med"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0160","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/BF01966996","article-title":"The mode of action of quinolones: the paradox in activity of low and high concentrations and activity in the anaerobic environment","volume":"10","author":"Lewin","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0165","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1128\/AAC.40.7.1594","article-title":"Fluoroquinolone action in mycobacteria: similarity with effects in Escherichia coli and detection by cell lysate viscosity","volume":"40","author":"Drlica","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl.B","key":"10.1016\/j.ijantimicag.2016.11.027_bib0170","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/13.suppl_B.9","article-title":"Investigations into the mechanism of action of the antibacterial agent norfloxacin","volume":"13","author":"Crumplin","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0175","first-page":"12","article-title":"Mechanisms of action of and resistance to ciprofloxacin","volume":"82","author":"Hooper","year":"1987","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0180","doi-asserted-by":"crossref","first-page":"e01741","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"MBio"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0185","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0190","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0195","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1128\/AAC.01182-08","article-title":"Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model","volume":"53","author":"Williams","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0200","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1128\/AAC.02819-14","article-title":"Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 2. Colistin","volume":"58","author":"Gontijo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0205","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0210","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/jac\/dku553","article-title":"Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients","volume":"70","author":"Heinrich","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.11.027_bib0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S1473-3099(16)30274-2","article-title":"High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial","volume":"17","author":"Boeree","year":"2017","journal-title":"Lancet"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T02:36:57Z","timestamp":1568774217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0924857917300298"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.027","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.11.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}